# Mettler Toledo International Inc/: financial statements, quarterly

MTD · NYSE · CIK 1037646 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mtd.md) · [Financials](/companies/mtd/financials.md) · [Filings](/companies/mtd/filings.md) · [Insiders](/companies/mtd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mtd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [942](/filings/0001037646-24-000034.md) | [935 d](/filings/0001037646-26-000011.md) | [926](/filings/0001037646-25-000021.md) | [947](/filings/0001037646-25-000040.md) | [955](/filings/0001037646-25-000058.md) | [1,045 d](/filings/0001037646-26-000011.md) | [884](/filings/0001037646-26-000021.md) | [983](/filings/0001037646-26-000051.md) | [1,030](/filings/0001037646-25-000058.md) | [1,130 d](/filings/0001037646-26-000011.md) | [947](/filings/0001037646-26-000021.md) | [1,027](/filings/0001037646-26-000051.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [560](/filings/0001037646-24-000034.md) | [552 d](/filings/0001037646-26-000011.md) | [548](/filings/0001037646-25-000021.md) | [566](/filings/0001037646-25-000040.md) | [572](/filings/0001037646-25-000058.md) | [639 d](/filings/0001037646-26-000011.md) | [526](/filings/0001037646-26-000021.md) | [580](/filings/0001037646-26-000051.md) | [609](/filings/0001037646-25-000058.md) | [675 d](/filings/0001037646-26-000011.md) | [556](/filings/0001037646-26-000021.md) | [650](/filings/0001037646-26-000051.md) |
| Research and development | $m | [46.1](/filings/0001037646-24-000034.md) | [46.4 d](/filings/0001037646-26-000011.md) | [46.4](/filings/0001037646-25-000021.md) | [45.8](/filings/0001037646-25-000040.md) | [47.1](/filings/0001037646-25-000058.md) | [50.1 d](/filings/0001037646-26-000011.md) | [46.3](/filings/0001037646-26-000021.md) | [49.3](/filings/0001037646-26-000051.md) | [51.1](/filings/0001037646-25-000058.md) | [52.6 d](/filings/0001037646-26-000011.md) | [51.3](/filings/0001037646-26-000021.md) | [53.0](/filings/0001037646-26-000051.md) |
| Selling, general and administrative | $m | [217](/filings/0001037646-24-000034.md) | [223 d](/filings/0001037646-26-000011.md) | [234](/filings/0001037646-25-000021.md) | [236](/filings/0001037646-25-000040.md) | [229](/filings/0001037646-25-000058.md) | [237 d](/filings/0001037646-26-000011.md) | [243](/filings/0001037646-26-000021.md) | [247](/filings/0001037646-26-000051.md) | [248](/filings/0001037646-25-000058.md) | [260 d](/filings/0001037646-26-000011.md) | [258](/filings/0001037646-26-000021.md) | [263](/filings/0001037646-26-000051.md) |
| Interest expense | $m | [20.3](/filings/0001037646-24-000034.md) | [19.7 d](/filings/0001037646-26-000011.md) | [19.2](/filings/0001037646-25-000021.md) | [19.0](/filings/0001037646-25-000040.md) | [18.6](/filings/0001037646-25-000058.md) | [17.9 d](/filings/0001037646-26-000011.md) | [16.7](/filings/0001037646-26-000021.md) | [16.8](/filings/0001037646-26-000051.md) | [17.7](/filings/0001037646-25-000058.md) | [17.4 d](/filings/0001037646-26-000011.md) | [17.0](/filings/0001037646-26-000021.md) | [17.2](/filings/0001037646-26-000051.md) |
| Income tax | $m | [49.5](/filings/0001037646-24-000034.md) | [47.8 d](/filings/0001037646-26-000011.md) | [43.0](/filings/0001037646-25-000021.md) | [21.4](/filings/0001037646-25-000040.md) | [47.4](/filings/0001037646-25-000058.md) | [62.2 d](/filings/0001037646-26-000011.md) | [38.4](/filings/0001037646-26-000021.md) | [46.3](/filings/0001037646-26-000051.md) | [51.7](/filings/0001037646-25-000058.md) | [43.3 d](/filings/0001037646-26-000011.md) | [40.2](/filings/0001037646-26-000021.md) | [56.5](/filings/0001037646-26-000051.md) |
| Net income | $m | [202](/filings/0001037646-24-000034.md) | [185 d](/filings/0001037646-26-000011.md) | [178](/filings/0001037646-25-000058.md) | [222](/filings/0001037646-25-000058.md) | [212](/filings/0001037646-25-000058.md) | [252 d](/filings/0001037646-26-000011.md) | [164](/filings/0001037646-26-000051.md) | [202](/filings/0001037646-26-000051.md) | [217](/filings/0001037646-25-000058.md) | [286 d](/filings/0001037646-26-000011.md) | [169](/filings/0001037646-26-000051.md) | [233](/filings/0001037646-26-000051.md) |
| Diluted EPS | $ per share | [9.21](/filings/0001037646-24-000034.md) | not reported | [8.24](/filings/0001037646-25-000021.md) | [10.37](/filings/0001037646-25-000040.md) | [9.96](/filings/0001037646-25-000058.md) | not reported | [7.81](/filings/0001037646-26-000021.md) | [9.76](/filings/0001037646-26-000051.md) | [10.57](/filings/0001037646-25-000058.md) | not reported | [8.33](/filings/0001037646-26-000021.md) | [11.55](/filings/0001037646-26-000051.md) |
| Basic EPS | $ per share | [9.26](/filings/0001037646-24-000034.md) | not reported | [8.28](/filings/0001037646-25-000021.md) | [10.42](/filings/0001037646-25-000040.md) | [10.01](/filings/0001037646-25-000058.md) | not reported | [7.84](/filings/0001037646-26-000021.md) | [9.78](/filings/0001037646-26-000051.md) | [10.60](/filings/0001037646-25-000058.md) | not reported | [8.35](/filings/0001037646-26-000021.md) | [11.57](/filings/0001037646-26-000051.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [69.7](/filings/0001037646-23-000035.md) | [69.8](/filings/0001037646-24-000034.md) | not reported | [70.8](/filings/0001037646-24-000027.md) | [71.6](/filings/0001037646-24-000034.md) | [59.4](/filings/0001037646-25-000058.md) | not reported | [61.8](/filings/0001037646-25-000040.md) | [69.1](/filings/0001037646-25-000058.md) | [66.9](/filings/0001037646-26-000051.md) | not reported | [51.4](/filings/0001037646-26-000051.md) |
| Current assets | $m | [1,197](/filings/0001037646-23-000035.md) | [1,230](/filings/0001037646-25-000012.md) | [1,211](/filings/0001037646-24-000012.md) | [1,178](/filings/0001037646-24-000027.md) | [1,198](/filings/0001037646-24-000034.md) | [1,194](/filings/0001037646-26-000011.md) | [1,165](/filings/0001037646-25-000021.md) | [1,244](/filings/0001037646-25-000040.md) | [1,281](/filings/0001037646-25-000058.md) | [1,363](/filings/0001037646-26-000051.md) | [1,332](/filings/0001037646-26-000021.md) | [1,347](/filings/0001037646-26-000051.md) |
| Total assets | $m | [3,289](/filings/0001037646-23-000035.md) | [3,356](/filings/0001037646-26-000011.md) | [3,283](/filings/0001037646-25-000021.md) | [3,249](/filings/0001037646-25-000040.md) | [3,320](/filings/0001037646-25-000058.md) | [3,240](/filings/0001037646-26-000011.md) | [3,235](/filings/0001037646-26-000021.md) | [3,400](/filings/0001037646-26-000051.md) | [3,521](/filings/0001037646-25-000058.md) | [3,713](/filings/0001037646-26-000051.md) | [3,669](/filings/0001037646-26-000021.md) | [3,671](/filings/0001037646-26-000051.md) |
| Current liabilities | $m | [1,070](/filings/0001037646-23-000035.md) | [1,181](/filings/0001037646-25-000012.md) | [1,132](/filings/0001037646-24-000012.md) | [1,281](/filings/0001037646-24-000027.md) | [1,185](/filings/0001037646-24-000034.md) | [1,168](/filings/0001037646-26-000011.md) | [1,150](/filings/0001037646-25-000021.md) | [1,107](/filings/0001037646-25-000040.md) | [1,192](/filings/0001037646-25-000058.md) | [1,198](/filings/0001037646-26-000051.md) | [1,108](/filings/0001037646-26-000021.md) | [1,201](/filings/0001037646-26-000051.md) |
| Total liabilities | $m | [3,395](/filings/0001037646-23-000035.md) | [3,505](/filings/0001037646-25-000012.md) | [3,442](/filings/0001037646-24-000012.md) | [3,402](/filings/0001037646-24-000027.md) | [3,474](/filings/0001037646-24-000034.md) | [3,367](/filings/0001037646-26-000011.md) | [3,417](/filings/0001037646-25-000021.md) | [3,659](/filings/0001037646-25-000040.md) | [3,771](/filings/0001037646-25-000058.md) | [3,736](/filings/0001037646-26-000051.md) | [3,711](/filings/0001037646-26-000021.md) | [3,658](/filings/0001037646-26-000051.md) |
| Long-term debt | $m | [1,929](/filings/0001037646-23-000035.md) | [1,889](/filings/0001037646-25-000012.md) | [1,904](/filings/0001037646-24-000012.md) | [1,747](/filings/0001037646-24-000027.md) | [1,892](/filings/0001037646-24-000034.md) | [1,831](/filings/0001037646-26-000011.md) | [1,891](/filings/0001037646-25-000021.md) | [2,124](/filings/0001037646-25-000040.md) | [2,146](/filings/0001037646-25-000058.md) | [2,088](/filings/0001037646-26-000051.md) | [2,162](/filings/0001037646-26-000021.md) | [2,045](/filings/0001037646-26-000051.md) |
| Current portion of debt | $m | [179](/filings/0001037646-23-000035.md) | [192](/filings/0001037646-25-000012.md) | not reported | [311](/filings/0001037646-24-000027.md) | [186](/filings/0001037646-24-000034.md) | [183](/filings/0001037646-26-000011.md) | not reported | [60.2](/filings/0001037646-25-000040.md) | [63.6](/filings/0001037646-25-000058.md) | [63.9](/filings/0001037646-26-000011.md) | not reported | [67.3](/filings/0001037646-26-000051.md) |
| Shareholders' equity | $m | [(106)](/filings/0001037646-24-000034.md) | [(150)](/filings/0001037646-26-000011.md) | [(159)](/filings/0001037646-25-000058.md) | [(153)](/filings/0001037646-25-000058.md) | [(154)](/filings/0001037646-25-000058.md) | [(127)](/filings/0001037646-26-000051.md) | [(182)](/filings/0001037646-26-000051.md) | [(259)](/filings/0001037646-26-000051.md) | [(249)](/filings/0001037646-25-000058.md) | [(23.6)](/filings/0001037646-26-000051.md) | [(41.9)](/filings/0001037646-26-000051.md) | [12.8](/filings/0001037646-26-000051.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [264 d](/filings/0001037646-24-000034.md) | [282 d](/filings/0001037646-26-000011.md) | [190](/filings/0001037646-25-000021.md) | [258 d](/filings/0001037646-25-000040.md) | [255 d](/filings/0001037646-25-000058.md) | [266 d](/filings/0001037646-26-000011.md) | [194](/filings/0001037646-26-000021.md) | [236 d](/filings/0001037646-26-000051.md) | [299 d](/filings/0001037646-25-000058.md) | [226 d](/filings/0001037646-26-000011.md) | [140](/filings/0001037646-26-000021.md) | [310 d](/filings/0001037646-26-000051.md) |
| Capital expenditure | $m | [21.0 d](/filings/0001037646-24-000034.md) | [32.4 d](/filings/0001037646-26-000011.md) | [17.4](/filings/0001037646-25-000021.md) | [23.8 d](/filings/0001037646-25-000040.md) | [21.4 d](/filings/0001037646-25-000058.md) | [41.3 d](/filings/0001037646-26-000011.md) | [17.3](/filings/0001037646-26-000021.md) | [23.9 d](/filings/0001037646-26-000051.md) | [24.5 d](/filings/0001037646-25-000058.md) | [41.5 d](/filings/0001037646-26-000011.md) | [17.4](/filings/0001037646-26-000021.md) | [27.8 d](/filings/0001037646-26-000051.md) |
| Share repurchases | $m | [224 d](/filings/0001037646-24-000034.md) | [176 d](/filings/0001037646-26-000011.md) | [212](/filings/0001037646-25-000021.md) | [212 d](/filings/0001037646-25-000040.md) | [212 d](/filings/0001037646-25-000058.md) | [213 d](/filings/0001037646-26-000011.md) | [219](/filings/0001037646-26-000021.md) | [219 d](/filings/0001037646-26-000051.md) | [219 d](/filings/0001037646-25-000058.md) | [144 d](/filings/0001037646-26-000011.md) | [206](/filings/0001037646-26-000021.md) | [206 d](/filings/0001037646-26-000051.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [22.6](/filings/0001037646-23-000035.md) | [22.3](/filings/0001037646-24-000012.md) | [22.1](/filings/0001037646-24-000027.md) | [21.9](/filings/0001037646-24-000034.md) | [21.5](/filings/0001037646-25-000021.md) | [21.4](/filings/0001037646-25-000040.md) | [21.2](/filings/0001037646-25-000058.md) | [20.9](/filings/0001037646-26-000021.md) | [20.7](/filings/0001037646-26-000051.md) | [20.6](/filings/0001037646-25-000058.md) | [20.3](/filings/0001037646-26-000021.md) | [20.2](/filings/0001037646-26-000051.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 20,036,559 at 2026-06-30, from the cover of the [10-Q filed 2026-07-31](/filings/0001037646-26-000051.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.